FDA – Page 64 – Pharma.Tips

Data exclusivity lapse risk during due diligence – documentation expectations for audits

“`html Understanding the Risks of Data Exclusivity Lapses During Due Diligence: Effective Investigation Strategies In an evolving pharmaceutical landscape, ensuring data exclusivity is of paramount importance. A lapse can expose…

Incident investigation incomplete during routine operations – CAPA escalation pathway

Improving Incomplete Incident Investigations during Routine Operations: A CAPA Approach In the pharmaceutical manufacturing landscape, incomplete incident investigations can pose significant challenges, leading to non-compliance with Good Manufacturing Practices (GMP)…

Freedom-to-operate gaps during development – preventing repeat IP exposure

Identifying and Addressing Freedom-to-Operate Gaps During Pharmaceutical Development Freedom-to-operate (FTO) gaps can represent significant risks during the pharmaceutical development process, potentially leading to costly delays and legal issues. In this…

Safety training gap during emergency response – how to withstand inspections

Examining Safety Training Gaps During Emergency Response for Inspection Readiness In the pharmaceutical manufacturing landscape, a robust emergency response plan is essential to ensure safety and compliance with regulatory standards.…

Partner IP obligations missed during due diligence – CAPA for IP control weaknesses

Identifying and Addressing Missed Partner IP Obligations During Due Diligence The pharmaceutical landscape increasingly involves collaboration, where partnering organizations share proprietary information essential for various stages of drug development and…

Permit condition violation during routine operations – how to withstand inspections

Addressing Permit Condition Violations in Routine Operations Permit condition violations can significantly compromise operational integrity and compliance in pharmaceutical manufacturing. Such violations may trigger regulatory scrutiny from agencies such as…

IP risks during tech transfer during lifecycle management – documentation expectations for audits

Addressing IP Risks in Tech Transfers During the Lifecycle Management of Pharmaceutical Products In the rapidly evolving pharmaceutical landscape, effective technology transfer is crucial to ensure the seamless transition of…

Waste handling non-compliance during routine operations – regulatory enforcement risk

Regulatory Risks and Investigation of Waste Handling Non-compliance in Routine Operations In the highly regulated world of pharmaceutical manufacturing, waste handling compliance is paramount. Non-compliance can lead to severe regulatory…

Data exclusivity lapse risk during development – preventing repeat IP exposure

Mitigating Risks of Data Exclusivity Lapse during Development in Pharma As the pharmaceutical industry advances, the importance of managing data exclusivity becomes increasingly apparent. Companies are often faced with the…

Chemical exposure incident during routine operations – compliance remediation strategy

Strategies for Addressing Chemical Exposure Incidents in Pharmaceutical Operations In the highly regulated landscape of pharmaceutical manufacturing, the risk of chemical exposure incidents during routine operations remains a significant concern.…

IP risks during tech transfer during lifecycle management – CAPA for IP control weaknesses

Mitigating Intellectual Property Risks During Tech Transfer in Lifecycle Management As the pharmaceutical landscape evolves, the need for effective tech transfer processes is paramount to ensure both product quality and…

Contractor safety breach during audit – CAPA escalation pathway

Addressing Safety Breaches by Contractors During Audits: A Comprehensive CAPA Approach In the highly regulated pharmaceutical environment, contractor safety breaches during audits can significantly jeopardize compliance and operational integrity. Such…